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OBJECTIVES: To estimate the annual number and frequency of
medical consultations for EGW in dermatology, gynecology,
proctology and in Sexually Transmitted Disease Clinics (STDC)
in France. METHODS: This is an observational study with
patients recruited prospectively from representative physicians
samples. Data related to the management of EGW was retrieved
for all patients suffering from EGW and willing to take part in
the study, during one 2-week period in June 2004. RESULTS:
The patients (n = 308) were recruited by the physician sample
that included 198 gynecologists, 102 dermatologists, 50 proc-
tologists and 122 physicians working in 51 STDCs. The annual
number of consultations for EGW is estimated at 423,751 (36%
for dermatologists, 53% for gynecologists, 6% for proctologists,
5% in STDC). The annual number of visits for a new episode of
EGW amounted to 160,247, representing 38% of the consulta-
tions. The annual frequency of consultation is 1,1 to 1.4% for
dermatologists and gynecologists and 4.4% to 5.1% for proc-
tologists. Almost half of the patients (43%) were seeking care
because of an EGW recurrence. EGW are treated using phar-
macological treatments and in-ofﬁce procedures (electrocoagu-
lation, cryotherapy, surgery, laser). Imiquimod treatment is used
as ﬁrst-line therapy is 40% of patients with a ﬁrst episode of
EGW and in 38% of patients presenting for an EGW recurrence.
CONCLUSION: Gynecologists are the most consulted special-
ists for EGW and proctologists have the highest annual fre-
quency of consultation. Various treatments are used to manage
EGW patients.
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OBJECTIVE: The American Academy of Dermatology guide-
lines provide a standard for appropriate pharmacological
therapy in psoriasis treatment. This survey study examined if
patients with severe psoriasis were on appropriate medications.
METHODS: A survey for this study was conducted by the
National Psoriasis Foundation between November and Decem-
ber 2004. A total of 400 interviews (telephone n = 188 and
online n = 212) were held with psoriasis and psoriatic arthritis
respondents. The respondents were asked questions regarding
their psoriasis. Some of these pertained to the type of medica-
tion participants were currently using. Respondents chosen from
a random sample were screened for a mix of gender and age.
Severity was categorized according to self-reported body surface
area involvement. Descriptive data were generated to determine
demographic characteristics of study population and prescrip-
tion patterns. RESULTS: Approximately 55% of the population
had severe psoriasis. Almost 50% of the population was on
topical therapy while 32% of the study sample was using sys-
temic medications for their psoriasis. About 19% of the study
population indicated that they were currently not on any treat-
ment. Almost 54% of these were suffering from severe psoria-
sis. A total of 157 patients with severe psoriasis were on some
form of topical therapy, however, only 63 of these were on con-
current recommended systemic therapy. As much as 60% of the
patients with severe psoriasis were on some form of topical
therapy alone to treat their psoriasis. CONCLUSIONS: Even
with such easily accessible guidelines in place, this study ﬁnds
that there are several people suffering from severe psoriasis that
are not on the recommended therapy in the United States. There
remains a need to inform both the patients and physicians about
appropriate pharmacotherapy to avoid further worsening of
health status of the patients involved.
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OBJECTIVES: To examine one-year patterns of topical acne pre-
scription medication use among enrollees of a US national phar-
macy beneﬁts management system. METHODS: We conducted
a one-year, retrospective, longitudinal cohort study of pharmacy
claims (i.e., prescription ﬁlls) for topical acne prescription med-
ications among continuously enrolled patients with at least one
claim for: retinoids (tazarotene, retinoic acid) or antimicrobials
(erythromycin, erythromycin with benzoyl peroxide, clin-
damycin, clindamycin with benzoyl peroxide, azelaic acid, 
sulfacetamide, benzoyl peroxide). We examined patient charac-
teristics (age, gender), proportion of patients using topical med-
ications as monotherapy or in combination with other targeted
medications, and average number of targeted medication claims
per patient. RESULTS: Among 76,407 identiﬁed patients, 11.4%
were under age 14, 35.3% age 14 to 17 years, 19.1% age 18 to
24 years, 9.2% age 25 to 31 years, 8.3% age 32 to 38 years,
6.9% age 39 to 45 years, and 9.8% over 45 years. Sixty-four
percent were female. Three quarters (74%) of patients used only
one targeted topical acne medication (i.e., monotherapy)
throughout the index year. Among patients receiving monother-
apy, total average number of claims was 2.3 (erythromycin, 1.7
claims; erythromycin with benzoyl peroxide, 2.4; clindamycin
2.8; clindamycin with benzoyl peroxide 2.7; azelaic acid, 2.3;
benzoyl peroxide, 2.8; sulfacetamide, 1.9; retinoids, 2.0). Among
patients receiving combined therapy, total average number of
antimicrobial claims was 2.2 and total number of retinoid claims
was also 2.2 Number of claims, types of topical acne prescrip-
tion medications, and other patterns of use did not signiﬁcantly
differ by age or gender. CONCLUSIONS: Overall, patients had
approximately two targeted prescriptions ﬁlls over a one-year
index period. Rates of prescription ﬁlls did not differ by class of
medication, patient age, or gender. Assumptions that females or
older patients are more compliant with their topical prescription
acne regimens were not supported by our ﬁndings.
PSN10
THE RISE OF THE GENERIC DRUG MARKET: IMPLICATIONS
FOR THE TREATMENT OF SKIN DISEASES
Bhosle M1, Balkrishnan R1, Feldman S2
1Ohio State University College of Pharmacy, Columbus, OH, USA;
2Wake Forest University School of Medicine, Winston Salem, NC,
USA
OBJECTIVE: In spite of a signiﬁcant growth in comparatively
inexpensive generic medications, the bioavailability concerns
associated with dermatological drugs make the generic substitu-
tion practices controversial for skin conditions. The objective of
this study was to analyze the trends in branded and generic drugs
used in dermatological conditions from 1990–2003. It also ana-
lyzed the overall trend in branded and generic drugs in the United
States. METHODS: A number of summary databases including
the National Ambulatory Medical Care Survey (NAMCS), NDC
Health Corporation’s Pharmaceutical Audit Suite (PHAST)
database, and the Food and Drug Administration resources from
1990–2003 were analyzed to obtain and compare information
on the manufacturing, production, patents and prescription 
of branded and generic drugs. These data were examined to
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examine which drugs had generic equivalents available for each
year. The Pharmaceutical Red Book was referred for drug pricing
and product information. RESULTS: Generic drugs accounted
for almost half of total prescription drugs dispensed in 2003 as
compared to 19% in 1983. In 1990, two of the ten drugs pre-
scribed in outpatient clinics were generics, which rose to six in
2003. Out of ten top-selling drugs, six drugs will lose their
patents in next ﬁve years. In 1990, none of the top ten derma-
tological drugs were generics. With few drugs losing their patents
since 1990 (e.g. Retin-A®), two out of top ten dermatological
drugs were generics in 2003. CONCLUSIONS: This study ﬁnds
an increasing trend in the availability of generic medications.
However, concerns regarding the bioavailability of generic equiv-
alents used in dermatological conditions may limit their use.
However, increased pressure from managed care organizations
to prescribe inexpensive generics, overall growth in generic drug
market, and anticipated drug patent expirations may inﬂuence
prescribing patterns of these medications.
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OBJECTIVE: To investigate the relationship between health
status, costs linked with the treatment of acne in the United
States and aspects related to medication use. METHODS: The
United States Medical Expenditure Panel Survey (MEPS) data-
base was analyzed for a cohort of people with acne. Patients for
this study were identiﬁed using the ICD-9 (International Classi-
ﬁcation of Diseases, 9th revision) code “706” for acne vulgaris
and similar conditions (The MEPS dataset uses only the ﬁrst
three digits of the ICD-9 codes to identify disease states). Records
of medical events were obtained using this ICD-9 code for acne
and the receipt of medication for acne. This cross sectional study
obtained costs, demographics, health care service utilization and
clinical patient variables from the MEPS database. The subjects
were divided into categories depending on type of medications
used, mainly, oral antibiotics, oral retinoids, oral contraceptives,
topical antibiotics, topical retinoids and oral contraceptives. The
EuroQOL (EQ-5D) scores available in MEPS for subjects 18
years and older were used for obtaining health status informa-
tion for these patients. Indices for medication adherence and
comorbidities were also calculated using the data from the
MEPS. Multivariate weighted analysis was performed on data
for approximately 5 million patients (weighted sample size).
RESULTS: Nearly 70% of the patients used some type of med-
ication for acne. Acne-related medication accounted for approx-
imately 36% of the total acne related health care costs, with an
average of 2 annual acne prescription reﬁlls. Increased number
of reﬁlls of acne speciﬁc drugs was associated with an improve-
ment in health status (p < 0.05). Increased ofﬁce based visits were
the only predictors of higher acne related health care costs (p <
0.01). CONCLUSIONS: Adherence to acne medications is an
important component of better health status. Pharmacological
treatment of acne does not signiﬁcantly add to acne-related
health care costs.
PSN12
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OBJECTIVES: To validate a scale for functional discomfort due
to nail psoriasis. The questionnaire will have to be adapted both
in the case of toe or ﬁnger nail psoriasis. The measured criterion
will be unidimensional and related to the bother caused by nail
psoriasis in daily life. METHODS: The scale was developed
according to the international recommendations on quality of
life. In October 2004, a questionnaire was sent to 4000
members, selected by drawing lots, among the French patients
support group (APLCP). The ﬁrst step of the process has led to
the selection of 10 items related to functional discomfort induced
by nail psoriasis. RESULTS: In total, 795 questionnaires con-
cerning individuals affected by nail psoriasis were analysed. Val-
idation analyses included the 10 selected items. Questionnaire’s
contents were coherent with the a-Cronbach coefﬁcient equaling
0.88. The unidimensional feature of the questionnaire was veri-
ﬁed: the analysis in principal components revealed that 49% of
the total variance was explained by one component. The DLQI
speciﬁc to dermatological pathologies was also given and
enabled a comparison with the scale. Pearson’s correlation coef-
ﬁcient between both scales was 0.48. The severity of the affec-
tion assessed through the DLQI evolved in the same way as the
evaluation for the “Nail Psoriasis” scale. A test-retest performed
on a sample of 15 individuals showed that the scale could be
reproduced with an intra-class correlation coefﬁcient of 0.82
between 2 administrations. CONCLUSION: The “Nail Psoria-
sis” scale is simple to use and easy to give to the patient. The
qualitative features which must be found in a quality of life scale
have been checked: comprehensibility, reliability and validity.
The scale will have to be used during clinical trials in order to
demonstrate its ability in measuring change in condition (before
and after treatment).
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Quality of life instruments are increasingly important in assess-
ing disease severity. However, some of these measurements have
been developed on a more or less ad hoc basis. Although not
well standardised, psychometric analyses can be used to re-test,
reﬁne and shorten existing quality of life instruments more
strictly. OBJECTIVES: To psychometrically test and reﬁne the
Impact of Psoriasis Questionnaire (IPSO) and to compare the
results of two different statistical approaches. METHODS:
Among 792 psoriasis patients who were included in the PUVA
Follow Up Study, we used Classical Test Theory (CTT) and
Rasch analysis to test and optimise the IPSO. Thereafter, two
shortened versions of the IPSO derived from these models were
compared. RESULTS: CTT analyses of the original IPSO demon-
strated suboptimal item performance for 6 of 16 items and inap-
propriate subscaling. In contrast to the original 4 subscales,
factor analysis of the CTT version yielded 3 subscales (mental
functioning, mental wellbeing and stigmatisation). The Rasch
approach, which included ordering of thresholds, differential
item functioning and item ﬁt, resulted in an unidimensional 11-
